Shares of Corcept Therapeutics (CORT) were slipping after the FDA updated a Complete Response Letter for the company’s relacorilant capsules, with the FDA saying that it informed the company “on several occasions” of its concerns about the adequacy of the clinical development program during pre-submission meetings. In the previous CRL, the FDA determined it could not approve the application in its present form. Shares of Corcept were nearly 11% lower in afternoon trading.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Corcept Therapeutics call volume above normal and directionally bullish
- Corcept’s TRIDENT Trial: Early Oncology Bet in Metastatic Pancreatic Cancer
- Corcept’s Nenocorilant Combo Study Moves Forward, Expanding Its Oncology Ambitions
- Corcept Therapeutics put volume heavy and directionally bearish
- Corcept Therapeutics price target raised to $100 from $99 at Canaccord